同步转移性肾细胞癌减瘤性肾切除联合完全转移灶切除术后第一年复发的危险因素
第一年复发者36例,其总生存显著短于延迟或无复发者(中位15 vs 97个月,P < .0001)。肝转移、原发肿瘤增大及术前C反应蛋白升高是第一年复发的预测因素。
要点
- 肝转移、原发肿瘤增大、术前CRP升高与第一年复发风险增加相关。
- 第一年复发者总生存显著缩短(中位15 vs 97个月)。
- 高危患者即使影像学NED,术后应考虑立即系统治疗。
核心结论
- 肝转移、原发肿瘤增大和术前C反应蛋白升高与减瘤性肾切除联合完全转移灶切除术后第一年进展风险增加相关。
- 尽管影像学达到NED状态,高危患者术后应考虑立即系统治疗,因其预后较差。
研究设计与样本
- 采用Kaplan-Meier法分析生存结局,逻辑回归模型识别第一年复发危险因素,决策曲线分析评估模型效用。
主要发现
- 第一年复发者总生存显著短于延迟/无复发者(中位15 vs 97个月,P < .0001)。
- 第一年复发预测因素包括肝转移、原发肿瘤增大和术前C反应蛋白升高。
- 纳入上述因素的预后模型具有判别能力,相比统一术后立即系统治疗或主动监测策略改善临床决策。
临床怎么用
- 对减瘤性肾切除联合完全转移灶切除术后达到M1 NED的患者,应评估肝转移、原发肿瘤大小及术前CRP以识别第一年复发高危者。
- 高危患者即使影像学NED,术后可考虑立即系统治疗而非主动监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients with metastatic renal cell carcinoma (mRCC) with oligometastatic disease can achieve radiographic disease-free (M1 NED) status after cytoreductive nephrectomy and concurrent complete metastasectomy. This study aimed to evaluate outcomes and identify risk factors associated with metastatic recurrence and overall survival in patients with mRCC M1 NED. MATERIALS AND METHODS: Patients with synchronous mRCC who were M1 NED after cytoreductive nephrectomy and concurrent complete metastasectomy from 4 institutions (2010-2020) were identified. Survival outcomes were analyzed by the Kaplan-Meier method. Patients were grouped by early (first year after surgery) recurrence or delayed/no known metastatic recurrence. Logistic regression modeling identified risk factors for first-year recurrence, and decision curve analysis evaluated the utility of a model incorporating identified risk factors. RESULTS: One hundred and nine M1 NED patients were identified including 36 patients who had recurrence in the first year after surgery and 73 patients with delayed or no recurrence. First-year recurrence resulted in significantly shorter overall survival compared with those with delayed/no recurrence after 1 year (median 15 vs 97 months, respectively, P < .0001). First-year recurrence predictors included liver metastases, increasing primary tumor size, and elevated preoperative C-reactive protein. A prognostic model incorporating these factors demonstrated discriminatory capacity and improved clinical decision-making compared with a universal immediate postoperative systemic therapy or active surveillance strategy. CONCLUSIONS: Liver metastasis, increasing primary tumor size, and elevated preoperative C-reactive protein are associated with increased risk for first-year progression after cytoreductive nephrectomy and complete metastasectomy. Despite radiographic NED status, high-risk patients should be considered for immediate systemic therapy after surgery given poor outcomes.
引用
- Ghasemzadeh A, Abel EJ, Karam JA, et al. Risk Factors for First-Year Recurrence in Patients With Synchronous Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy and Complete Metastasectomy. J Urol. 2025. PMID: 40763351. doi:10.1097/JU.0000000000004705
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。